Reversible sideroblastic anemia associated with the tetracycline analogue COL-3.
Eight of 35 patients with cancer receiving COL-3, a tetracycline derivative with antiangiogenic properties, developed anemia while on treatment. All of these patients were enrolled on an approved Phase I clinical trial at the National Cancer Institute. Three of these patients had bone marrow examinations that revealed ringed sideroblasts. This paper describes these cases. Am. J. Hematol. 67:51-53, 2001. Published 2001 Wiley-Liss, Inc.
Rudek
M A
MA
Medicine Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Horne
M
M
Figg
W D
WD
Dahut
W
W
Dyer
V
V
Pluda
J M
JM
Reed
E
E
D018263:Adenocarcinoma, Follicular / Q000150:complications / Q000188:drug therapy; D000328:Adult; D000756:Anemia, Sideroblastic / Q000139:chemically induced*; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D001853:Bone Marrow / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013752:Tetracycline / Q000008:administration & dosage / Q000009:adverse effects*; D013754:Tetracyclines; D013964:Thyroid Neoplasms / Q000150:complications / Q000188:drug therapy
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D013754:Tetracyclines; C117155:tetracycline CMT-3; D013752:Tetracycline